What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2021-10-27 compared with 2020-11-16 · 44 added, 74 removed, 3 unchanged (98% of the section changed)

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY,

RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

ITEM 5 – MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED

STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

The Company’s common stock, par value $0.001

$0.001 per share, trades on the Nasdaq Capital Market under the symbol “SLP.”

Price Range of Common Stock

The following table shows high and low

sales prices for the Company’s common stock for each quarter during the past two fiscal years:

Quarter ended November 30, 2018

Quarter ended February 28, 2019

Quarter ended May 31, 2019

Quarter ended August 31, 2019

Quarter ended November 30, 2019

Quarter ended February 29, 2020

Quarter ended May 31, 2020

Quarter ended August 31, 2020

of November 16, 2020, there were 46 shareholders of record.

We paid a total of approximately $4.3 million

in cash dividends during fiscal year 2020, and $4.2 million in fiscal year 2019 as set forth in the table below.

We expect to pay

quarterly dividends of $0.06 per share of common stock each quarter, subject to declaration by our Board of Directors.

there can be no assurances that our Board of Directors will continue the dividend distributions for any specified number of quarters.

per share, has traded on the Nasdaq Global Select Market under the symbol “SLP ”

since May 13, 2021, prior to which it traded on the Nasdaq Capital Market under the same symbol.

As of October 25, 2021, there were 43 shareholders

A substantially greater number of holders of our common stock are “street name” or beneficial holders, whose

shares are held by banks, brokers and other financial institutions.

The following dividends were declared by our

Board of Directors during the fourth quarter of fiscal year 2021:

(in thousands, except dividend per share amounts)

Outstanding on

Although we expect to pay quarterly dividends

of $0.06 per share of common stock each quarter, the dividend is subject to declaration by our Board of Directors.

There can be no assurances

that our Board of Directors will continue the dividend distributions for any specified number of quarters.

Refer to Note 8 – Shareholders’

Equity of the Notes to Financial Statements (Part II, Item 8 of this Annual Report on Form 10-K) for further details regarding dividends.

Shareholder Return Performance Graph

The following graph compares the cumulative

total stockholder return on our common stock of a $100 investment from August 31, 2016 through August 31, 2020 assuming reinvestment

of dividends, with a similar investment in the Russell 3000 index (the “Russell 3000”) and with the companies listed

in the Nasdaq Composite - Total Returns (“IXIC”), and the S&P600 Health Care Equipment & Services Industry

Group Index (SP600-3510).

The historical information set forth below is not necessarily indicative of future performance.

performance graph shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as

amended or incorporated by reference into any of our filings under the Securities Act of 1933, as amended, of the Exchange Act,

except as shall be expressly set forth by specific reference in such filing.

There is currently no share repurchase

program pending, and the Company has made no repurchases of its securities since fiscal year 2011.

ITEM 6 – SELECTED FINANCIAL DATA

The following tables set forth the selected

consolidated financial data for each of the fiscal years in the five-year period ended August 31, 2020.

We derived the selected

consolidated financial data from our audited consolidated financial statements, which should be read in conjunction with Item 7,

Management’s Discussion and Analysis of Financial Condition and Results of Operations in Part II of this Annual Report on

Form 10-K and our consolidated financial statements and the related notes included elsewhere in this report.

Year ended August 31,

Statements of operations data

Cost of revenues

SG&A expenses

Total operating expenses

Income from operations

Other income (expense)

Income from operations before income taxes

Provision for income taxes

Earnings per share

Weighted-average common shares outstanding

Dividend per common share

Other comprehensive Income (Loss), net of tax

Foreign currency translation adjustments

As of August 31,

Balance sheet data at year end

Cash and cash equivalents

Net working capital

$ 123,586,788

$ 168,421,517

Total liabilities associated with business and intangible acquisitions

Total liabilities

Total shareholders’ equity

$ 156,035,945

Notes to Five-Year Summary

[a] Effective June 1, 2017, we acquired

DILIsym Services, Inc.

and incurred approximately $620,000 of acquisition related costs in FY2017.

[b] In FY2018 we posted a $1.5 million

deferred tax benefit due to the effect of new tax rates enacted under the Tax Cuts and Jobs Act of 2017.

[c] Effective April, 2020, we acquired

Lixoft and incurred approximately $1,416,000 of acquisition-related costs in FY2020.

[d] In August 2020 the company issued 2,090,909

of shares in a follow-on public offering, priced at $55.00 per share.

Net proceeds from this offering after underwriting discounts

and commissions and other offering expenses were $107.7 million.

The following graph compares the cumulative total

stockholder return on our common stock of a $100 investment from August 31, 2017 through August 31, 2021, assuming reinvestment of dividends,

with a similar investment in the Russell 3000 index (the “Russell 3000”) and with the companies listed in the Nasdaq Composite

- Total Returns (“IXIC”), and the S&P600 Health Care Equipment & Services Industry Group Index (SP600-3510).

The historical

information set forth below is not necessarily indicative of future performance.

This performance graph shall not be deemed “filed”

for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference into any of our filings under

the Securities Act of 1933, as amended, of the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Recent Sales of Unregistered Securities;

Use of Proceeds from Registered

On June 1, 2021, we issued an aggregate of 11,540 unregistered shares

of our common stock to the former owners of Lixoft pursuant to that Share Purchase and Contribution Agreement, dated March 31, 2020, entered

into between the Company and such former owners.

The shares had an aggregate value of $666 thousand and were issued as an earnout payment

in connection with the satisfaction of certain year-over-year performance thresholds set forth in the Share Purchase and Contribution

The shares of common stock were issued in a transaction not involving

a public offering in reliance upon an exemption from registration provided by Section 4(a)(2) of the Securities Act, and/or Regulation

S promulgated thereunder.

During the fiscal year ended August 31, 2021,

there were no other unregistered sales of our securities that were not reported in a Current Report on Form 8-K or our Quarterly Reports

on Form 10-Q.

There is currently no share repurchase program

pending, and the Company has made no repurchases of its securities since fiscal year 2011;

however, the Board of Directors may decide

to institute such a program in the future.

ITEM 6 – [RESERVED]

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity